Dr. Nilüfer Ertekin-Taner, a renowned physician-scientist and professor at Mayo Clinic, is spearheading a transformative $41 million research program known as CLEAR-AD. This initiative focuses on advancing Alzheimer's research within multiethnic populations, including traditionally understudied groups like African Americans and Latino Americans. The program aims to identify precision medicine biomarkers and therapeutic targets for Alzheimer's by analyzing blood and brain tissue samples. This research is funded by a National Institutes of Health grant and seeks to understand the molecular underpinnings of the disease. Ultimately, it aspires to predict Alzheimer's development, the speed of progression, and discover precision medicine treatments. Collaborating with several institutions, Dr. Ertekin-Taner's work highlights the urgency of addressing Alzheimer's disease and emphasizes inclusivity in medical research.
Mayo Clinic's grant to advance multiethnic Alzheimer’s research. Nilufer Ertekin-Taner, M.D., Ph.D.
event30th Nov 2023
schedule7:00 - 8:00pm (GMT)
event
30th Nov 2023
7:00 - 8:00pm (GMT)
place
Hosted on MedAll
event_available
This event has ended. Similar events
Free
ONLINE
Description
Summary
Come learn from Dr. Nilüfer Ertekin-Taner, Mayo Clinic's leading expert on Alzheimer's disease research, as she presents her progressive program to advance multiethnic research in Alzheimer's at a special medical session. The program, funded by a generous NIH grant, focuses on identifying biomarkers and therapeutic targets in the blood and brain tissue of understudied multiethnic populations to create new strategies for predicting the progression and discovering effective treatments of the disease. Don't miss this opportunity to hear about this groundbreaking research and contribute to a collective effort to further medical progress.
smart_toy Generated by MedBot
Learning objectives
- Learners should be able to articulate the purpose of the CLEAR-AD research program.
- Learners should be able to explain how the program seeks to identify precision medicine biomarkers and therapeutic targets for Alzheimer's.
- Learners should be able to identify the funding sources and the institutions collaborating for the CLEAR-AD program.
- Learners should be able to recognize the importance of inclusivity in research in traditionally understudied multiethnic populations.
- Learners should be able to describe the ultimate goal of the program, which is to predict Alzheimer's progression and discover precision medicine treatments.
smart_toy Generated by MedBot
Speaking at this event
Similar events and on demand videos
event
30th Nov 2023
7:00 - 8:00pm (GMT)
place
Hosted on MedAll
event_available
This event has ended. Similar events
Free
ONLINE